2-(p-hydroxyphenyl)-4-methylimidazole | 91944-46-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(p-hydroxyphenyl)-4-methylimidazole
• 英文别名: 4-(5-methyl-1H-imidazol-2-yl)phenol
• CAS: 91944-46-6
• 化学式: C₁₀H₁₀N₂O
• 分子量: 174.202
• InChiKey: XXYIEINHVTWJRP-UHFFFAOYSA-N

物化性质

• 沸点：
  426.2±28.0 °C(Predicted)
• 密度：
  1.235±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  48.9
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(p-hydroxyphenyl)-4-methylimidazole 生成 2-[p-(3-Cyclopropylamino-2-hydroxypropoxy)phenyl]-4-methylimidazole
  参考文献：
  名称：

  .beta.-blocking substituted imidazoles

  摘要：

  揭示了一种新型替代咪唑并其制备方法。这些咪唑及其盐具有药理活性，包括抗高血压活性和β-肾上腺素能阻断活性。

  公开号：

  US04853383A1

文献信息

• .beta.1-Selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted amino)-2-hydroxypropoxy]phenyl]imidazole class. II
  作者：John J. Baldwin、Marcia E. Christy、George H. Denny、Charles N. Habecker、Mark B. Freedman、Paulette A. Lyle、Gerald S. Ponticello、Sandor L. Varga、Dennis M. Gross、Charles S. Sweet

  DOI：10.1021/jm00156a028

  日期：1986.6

  exploring structure-activity relationships around (S)-[p-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-hydroxypropoxy] phenyl]-4-(2-thienyl)imidazole. Strategies to reduce or eliminate ISA centered on structural changes that could influence activation of the receptor by the drug itself or by a metabolite. The approaches involved (a) eliminating the acidic imidazole N-H proton, (b) incorporating substituents

  缺乏内在拟交感活性（ISA）的高心脏选择性β-肾上腺素受体拮抗剂的开发尝试着眼于探索围绕（S）-[p- [3-[[2-（3,4-二甲氧基苯基）乙基]的构效关系氨基] -2-羟基丙氧基]苯基] -4-（2-噻吩基）咪唑。减少或消除ISA的策略集中于可能影响药物本身或代谢产物激活受体的结构变化。这些方法涉及（a）消除酸性咪唑NH质子;（b）结合邻位至β-肾上腺素能阻断侧链的取代基;（c）增加NH部分周围的空间体积;（d）降低亲脂性;（e）引入分子内涉及咪唑NH的氢键，以及（f）通过引入间隔基使咪唑环从活化位置移位。体外研究了这些化合物的β-肾上腺素受体拮抗作用，体内研究了ISA。从这些研究中，最成功的变化涉及在咪唑和芳基环之间插入间隔基。证明了（S）-4-乙酰基-2-[[4- [3-[[2-（3,4-二甲氧基苯基）乙基]氨基] -2-羟基丙氧基]苯基]甲基]咪唑（S-51）具有高度的心脏选择性（剂量比β2
• .beta.-adrenergic blocking imidazolylphenoxy propanolamines
  申请人：Merck & Co., Inc.

  公开号：US04642311A1

  公开（公告）日：1987-02-10

  Substituted imidazoles and methods for their preparation are disclosed. These imidazoles, and their salts, exhibit pharmacological activity which includes antihypertensive activity and .beta.-adrenergic blocking activity. ##STR1##

  公开了取代咪唑和其制备方法。这些咪唑及其盐表现出药理活性，包括降压活性和β-肾上腺素受体阻滞活性。
• 3-Amino-2-hydroxypropoxyaryl imidazole derivatives
  申请人：Merck & Co., Inc.

  公开号：US04440774A1

  公开（公告）日：1984-04-03

  Novel substituted imidazoles of the formula ##STR1## and methods for their preparation are disclosed. These imidazoles, and their salts, exhibit pharmacological activity which includes antihypertensive activity and .beta.-adrenergic blocking activity.

  揭示了公式为##STR1##的新型取代咪唑类化合物以及它们的制备方法。这些咪唑类化合物及其盐表现出药理活性，包括抗高血压活性和β-肾上腺素受体阻滞活性。
• Method of rate enhancement for triester synthesis of oligonucleotides using a catalytic alcohol, and compounds for use therein
  申请人：GENENTECH, INC.

  公开号：EP0163405A2

  公开（公告）日：1985-12-04

  The rate of the triester method of oligonucleotide synthesis is increased by using a phosphotriester formation catalyst/blocking group diester linked to the 3' phosphate of a nucleotide (or an oligonucleotide), thus forming a nucleotide phosphodiester: Insert here wherein Base is a nucleotide base; wherein Pr is a nucleotide 5' hydroxyl protecting group, for example, monomethoxytrityl or dimethoxytrityl; wherein R includes a substituted or unsubstituted, aryl, alkyl, cycloalkyl or beta cyanoalkyl blocking group; wherein CAT is a catalytic moiety, which is, for example, a substituted or unsubstituted, nitrogen heterocycle, tertiary amine or a carboxylic acid. The use of these groups so linked to form nucleotide phosphodiesters enhances the rate of an internucleotide condensation reaction. Following condensation (which results in the formation of a phosphotriester) the phosphotriester formation catalyst/blocking group can be removed leaving a di-nucleotide, or the condensation reaction can be repeated to synthesize an oligonucleotide.

  使用与核苷酸（或寡核苷酸）的 3'磷酸相连的磷酸二酯形成催化剂/阻断基团二酯，从而形成核苷酸磷酸二酯，可提高寡核苷酸合成三酯法的速率： 此处插入 其中 Base 是核苷酸碱基； 其中 Pr 是核苷酸 5'羟基保护基团，例如单甲氧基三苯甲基或二甲氧基三苯甲基； 其中 R 包括取代或未取代的芳基、烷基、环烷基或 β-氰基烷基封端基团； 其中 CAT 是催化分子，例如是取代或未取代的氮杂环、叔胺或羧酸。 使用这些基团连接形成核苷酸磷酸二酯可提高核苷酸间缩合反应的速率。缩合（形成磷酸二酯）后，可去除磷酸二酯形成催化剂/阻断基团，留下二核苷酸，或重复缩合反应，合成寡核苷酸。
• .beta.1-Selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted-amino)-2-hydroxypropoxy]phenyl]imidazole class
  作者：John J. Baldwin、George H. Denny、Ralph Hirschmann、Mark B. Freedman、Gerald S. Ponticello、Dennis M. Gross、Charles S. Sweet

  DOI：10.1021/jm00361a004

  日期：1983.7

  A series of 2-[4-[3-(substituted-amino)-2-hydroxypropoxy]phenyl]imidazoles is described. The compounds were investigated in vitro for beta-adrenoceptor antagonism, and several examples were found to be selective for the beta 1-adrenoceptor. The structure--activity relationship exhibited by this series of compounds is discussed. (S)-2-[p-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-hydroxypropoxy]phenyl]-4-(2 -thienyl)imidazole [(S)-13] was over 100 times more selective than atenolol for the beta 1-adrenergic receptor and has been selected for in-depth studies.